Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IMBRUVICA (Treatment A) Clear all
Completed Phase 1Phase 2 Interventional

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

NCT03740529
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib, Venetoclax, Rituximab
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
31
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02744612
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Ibrutinib
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Duarte, California • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 10, 2026, 10:14 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04607772
View directory record Official record
Conditions
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions
Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

NCT02599324
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Interventions
ibrutinib, everolimus, paclitaxel, docetaxel, cetuximab, pembrolizumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
44
States / cities
Huntsville, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 10, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01886859
View directory record Official record
Conditions
Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Results available

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

NCT02303392
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
Selinexor, Ibrutinib, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 10, 2026, 10:14 PM EDT
Active, not recruiting Phase 1 Interventional

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

NCT02787369
View directory record Official record
Conditions
Recurrent Chronic Lymphoid Leukemia
Interventions
ACY-1215, Ibrutinib, Idelalisib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
1 Year to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Duarte, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

NCT02562898
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ibrutinib, Paclitaxel, Gemcitabine
Drug
Lead sponsor
Margaret Tempero
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

NCT04294641
View directory record Official record
Conditions
Chronic GVHD
Interventions
Ibrutinib, ECG, PFT's, CT, Steroid pulse (prednisone), Voriconazole, Posaconazole, Azithromycin, Montelukast, Budesonide, Beclomethasone, Filgrastim, Pegfilgrastim, Erythropoietin, Transfusions, Oral/Skin biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Active, not recruiting Phase 1 Interventional

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

NCT03479268
View directory record Official record
Conditions
B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat, Pharmacokinetic Study, Pharmacological Study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Duarte, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

NCT03447808
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Daratumumab, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813
View directory record Official record
Conditions
Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Quality-of-Life Assessment, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
781
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

NCT02436668
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ibrutinib, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Huntsville, Alabama • Avondale, Arizona • Daly City, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 10, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

NCT05643235
View directory record Official record
Conditions
Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 10, 2026, 10:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536
View directory record Official record
Conditions
Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Nemtabrutinib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
Interventions
Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • New Hyde Park, New York • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

NCT02557516
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
monalizumab
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Active, not recruiting Early Phase 1 Interventional

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

NCT03684980
View directory record Official record
Conditions
Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, leucovorin, Glucarpidase
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

NCT02415608
View directory record Official record
Conditions
Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
Interventions
Ibrutinib
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 10, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02518555
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 10, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

NCT03876028
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Ibrutinib
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 10, 2026, 10:14 PM EDT